Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.
Financial Results:
Suven Pharmaceuticals Ltd reported Revenues for Q1FY25 of ₹231.00 Crores down from ₹348.00 Crore year on year, a fall of 33.62%.
Total Expenses for Q1FY25 of ₹166.00 Crores down from ₹195.00 Crores year on year, a fall of 14.87%.
Consolidated Net Profit of ₹61.00 Crores down 49.59% from ₹121.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹2.39, down 49.58% from ₹4.74 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.